Лучшие больницы для «Myomectomy (Fibroid Removal Surgery)» в Хайдарабад, Индия

The total cost of myomectomy depends primarily on the surgical approach chosen (hysteroscopic, laparoscopic/robotic, or open abdominal), the number and size of fibroids, the hospital tier, and the city. In India, at JCI- and NABH-accredited hospitals such as Apollo, Fortis, or Manipal, the all-inclusive cost typically ranges from approximately USD 2,500 to USD 7,000. This range covers hysteroscopic myomectomy at the lower end (USD 2,500–3,500), laparoscopic myomectomy (USD 3,500–5,500), and robotic-assisted or complex open myomectomy at the higher end (USD 5,000–7,000), including the surgeon's fee, anesthesia, hospital stay, standard medications, and operating theater charges. In the UAE — at JCI- and DHA-accredited institutions such as Cleveland Clinic Abu Dhabi or the American Hospital Dubai — equivalent procedures cost approximately USD 5,500 to USD 15,000, reflecting higher facility and physician fee structures. India thus delivers comparable or superior surgical expertise at 40–60% lower cost than the UAE, making it the preferred destination for patients prioritizing cost-efficiency. Additional costs to budget for in both destinations include pre-operative investigations (MRI pelvis, blood panel: approximately USD 200–600), accommodation during the post-operative in-country recovery period, and return airfare. GAF Healthcare provides a detailed, personalized cost estimate after reviewing the patient's medical records and fibroid mapping.

The minimum safe in-country stay before an international flight depends directly on the surgical approach used. For hysteroscopic myomectomy (no abdominal incisions), most patients are fit to fly within 7–10 days of surgery, provided they are afebrile, have no signs of fluid overload complications, and histopathology results are available. For laparoscopic or robotic-assisted myomectomy, the standard recommendation is to remain in-country for at least 2–3 weeks post-operatively. This allows time for wound healing, confirmation that there is no internal bleeding or infection, and receipt of the final histopathology report (typically 5–7 business days). For open (abdominal) myomectomy — involving a Pfannenstiel or midline laparotomy incision — patients should plan for a minimum of 4–6 weeks in-country before flying, as abdominal wall healing must be sufficiently advanced to tolerate the pressure changes and immobility of long-haul travel. A critical consideration for all surgical approaches is DVT (deep vein thrombosis) risk: long-haul flights (>4–6 hours) significantly elevate thromboembolism risk in recent post-operative patients. GAF Healthcare's medical team will assess each patient's individual DVT risk profile before issuing a 'fit to fly' clearance, and low-molecular-weight heparin (LMWH, e.g., enoxaparin) injections are typically prescribed for the return flight if travel occurs within 4 weeks of surgery. Compression stockings during the journey are also mandatory. Your GAF Healthcare Case Manager will coordinate the formal medical clearance letter required by most airlines for post-surgical travel.

Myomectomy is highly effective for its primary goals — relief of symptoms and uterine preservation. Symptom resolution rates (reduction in heavy bleeding, pelvic pain, and bulk symptoms) are reported at 90–95% across large case series and systematic reviews, including data from high-volume Indian and UAE centers. For patients undergoing myomectomy specifically to improve fertility, published evidence demonstrates a clinically meaningful improvement in conception rates: meta-analyses show that removal of submucosal fibroids (FIGO Types 0–2) normalizes clinical pregnancy rates to those of fibroid-free women, and removal of intramural fibroids distorting the cavity improves IVF live birth rates by approximately 40–50%. The more nuanced issue is fibroid recurrence, which is the key limitation of myomectomy compared to hysterectomy (the only definitive cure). Recurrence rates are approximately 15–30% at 5 years and 40–50% at 10 years, with the highest recurrence risk in women under 35 years of age, those with multiple fibroids at the index operation (>3 fibroids), and those with a strong family history of fibroids. Not all recurrent fibroids become symptomatic or require re-intervention. Post-operative medical suppression strategies — such as a levonorgestrel-releasing intrauterine system (LNG-IUS, e.g., Mirena) fitted at the time of hysteroscopic myomectomy, or progestins/low-dose GnRH antagonist add-back therapy — are used at leading centers to delay recurrence, particularly in patients who have completed childbearing but wish to defer hysterectomy. GAF Healthcare's partner surgeons provide individualized recurrence risk counseling based on the number, size, and type of fibroids removed, and long-term follow-up with annual pelvic ultrasound surveillance is incorporated into the post-treatment care plan.